natgillin/translations-raw huggingface dataset:
A kit for providing a therapeutic dietary regimen comprising a plurality of foods for the preparation of a subject's bowel for a medical procedure, wherein the kit comprises low fiber, low residue foods sufficient for all of the meals to be ingested by the subject for a specified period prior to the medical procedure, and wherein the low fiber, low residue foods have incorporated therein a laxative agent selected from the group consisting of polyethylene glycol (PEG), dibasic sodium phosphate, monobasic sodium phosphate, sodium biphosphate, magnesium hydroxide, and magnesium sulfate, and further wherein the laxative agent is in an amount sufficient to induce in the subject the production of watery yellow stools with a light yellow effluent. 
HR P20171852 T1 PATENTNI ZAHTJEVI no Komplet za pružanje terapijskog dijetetskog režima koji obuhvaća više namirnica za pripremu crijeva pacijenta za medicinski postupak, pri čemu taj komplet sadrži malu količinu vlakna, malo ostataka hrane dovoljne za sve obroke koje pacijent treba progutati za predviđeni period prije medicinskog postupka, i pri čemu malo vlakna, malo ostataka hrane sadrži u sebi laksativno sredstvo odabrano iz skupine koja sadrži polietilen glikol (PEG), dvobazni natrij fosfat, monobazni natrij fosfat, natrij bifosfat, magnezij hidroksid, i magnezij sulfat, i pri čemu je još laksativno sredstvo u količini dovoljnoj inducirati kod pacijenta proizvodnju razvodnjene žute stolice sa svijetlo žutom tekućinom.
The composition according to claim 1, further comprising a non-evaporating oily co-solvent selected from at least one of the following solvent classes a compound of general formula I H(OCH2C(CH3)H)xOR1 
Kompozicija prema bilo kojem od zahtjeva 1-5 koja dalje sadrži ne-isparljivi uljni ko-rastvarač koji je izabran iz najmanje jedne od sljedećih klasa rastvarača
or pharmaceutically acceptable salt thereof. A compound according to claim 1 which is 3-[[6-(1,3-benzodioxol-5-yl)-3-methyl-pyridine-2-carbonyl]amino]-2,4-dimethyl-benzoic acid; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[6-(1,3-benzodioksol-5-11)-3-metilpiridin-2karboniljamino]-2,4-dimetilbenzojeva kiselina; ili njezina farmaceutski prihvatljiva sol.
The method according to one of the preceding variants, wherein the step of measuring at least one further physical quantity comprises measuring a distance between the anchor and a fixed reference point, in particular measuring a distance between the anchor and a water vessel. 
Postupak prema jednom od prethodnih patentnih zahtjeva, pri čemu korak mjerenja najmanje jedne daljnje fizikalne veličine obuhvaća mjerenje udaljenosti između sidra 1 fiksne referentne točke, osobito mjerenje udaljenosti između sidra 1 plovila (2) 1ili mjerenje nagiba ili orijentacije sidra.
The present invention relates to buprenorphine or a pharmaceutically acceptable salt, ether derivative, ester derivative, acid derivative, enantiomer, diasteriomer, racemate, polymorph, or solvate thereof. 
Ovaj se izum odnosi na buprenorfin ili njegovu farmaceutski prihvatljivu sol, eterski derivat, esterski derivat, kiselinski derivat, enantiomer, diastereomer, racemat, polimorf ili solvat.
The wear member according to anyone of the preceding claims, characterized that an opening (101) for receiving a lock (16) to secure the wear member (14) to the base (12) is provided. 
Zub bagera prema zahtjevu 1, naznačen time, da je predviđen otvor (101) za prihvat zasuna (16) u svrhu osiguravanja zuba bagera (14) na bazi (12).
The method as in any one of the preceding embodiments, wherein the binder is a blank ink (11) comprising a liquid substance that is applied by a digital drop application head (30 ′). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što je tekuće vezivo bezbojna tinta (11) koja sadrži tekuću supstancu koja se primjenjuje pomoću digitalne aplikacijske glave (30).
in part (h), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:127 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 126; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 127 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 126;
and X2 are independently hydrogen, halo, hydroxy, amino or oxo, provided that X1 is not oxo when carbon atoms 12 and 13 are connected to one another with a double bond, further provided that X2 is not oxo when carbon atoms 9 and 11 are connected to one another with a double bond; 
, naznačen time što: i X2 su neovisno vodik, halogen, hidroksi, amino ili okso, uz uvjet da X1 nije okso kada su atomi ugljika 12 i 13 međusobno spojeni dvostrukom vezom, uz dodatno uvjet da X2 nije okso kada su atomi ugljika 9 i 11 međusobno spojeni dvostrukom vezom;
A pharmaceutical composition according to any one of claims 1 to 5 for use in the treatment or prophylaxis of a disease, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by Mps-1, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, e.g . 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5 naznačen time da je za upotrebu za liječenje ili sprječavanje bolesti, pri čemu navedena bolest je bolest nekontroliranog rasta stanica, proliferacija i/ili preživljavanje, neodgovarajući stanični imuni odgovor, ili neodgovarajući stanični upalni odgovor, naročito u kojem je nekontrolirani rast stanica, proliferacija 1/ili preživljavanje, neodgovarajući stanični imuni odgovor, ili neodgovarajući stanični upalni odgovor, posredovan sa Mps-1l, naročito u kojem bolest nekontroliranog rasta stanica, proliferacija i/ili preživljavanje, neodgovarajući stanični imuni odgovor ili neodgovarajući stanični upalni odgovor je hematološki tumor, solidni tumor i/ili njegove metastaze, npr.
preparation of #3 Extract: Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Spica Prunellae, Concha Margaritifera Usta and Herba Asari are combined, decocted with 4∼10 fold of water for 2∼3 times, the first time for 0.5∼3 hours, the second and/or third time for 1∼3 hours, filtered, concentrated until the relative density is 1.06∼1.10 at 75∼85°C, into which ethanol is added to make a final ethanol content of 60∼85%, left to stand still for 12∼24 hours, and filtered; and the ethanol is recovered and concentrated until the relative density is 1.270∼1.350 at 75∼85°C to give #3 Extract for later use; 
Priprema ekstrakta br. 3: Radix Rehmanniae Preparata, Ramulus Uncariae cum Uncis, Caulis Spatholobi, Špica Prunellae, Concha Margaritifera Usta i Herba Asari se pomiješaju, ukuhavaju 2 do 3 puta s 4 do 10 puta većom količinom vode, prvi put u trajanju od 0,5 do 3 sata, drugi i / ili treći put u trajanju od 1 do 3 sata, profiltriraju, koncentriraju do relativne gustoće 1,06 ~ 1,1°C na 75 do 85°C u koje se dodaje etanol kako bi se dobila konačna koncentracija etanola od 60% ~ 85%, ostavi stajati 12 do 24 sata i filtrira; izdvaja i koncentrira do relativne gustoće 1.270 ~ 1.350 na 75 do 85°C da se dobije ekstrakt br. 3 za kasniju uporabu;
A cylinder lock (1) according to claim 4, wherein the cylinder lock further comprises an external connection apparatus (16) connected to said connector (14). 
Cilindrična brava (1) prema zahtjevu 4, naznačena time da cilindrična brava nadalje sadrži vanjski konektorski aparat (16) spojen s navedenim konektorom (14).
Another embodiment is directed to the crystalline sodium salt of Compound (1) having an XRPD pattern comprising a peak at 10.1 degrees 2θ (±0.2 degrees 2θ) as described above and further comprising peaks at 13.0 and 18.2 degrees 2θ (±0.2 degrees 2θ) when measured using CuKa radiation. 
Kristalna natrijeva sol prema zahtjevu 3, naznačena time, da uzorak difrakcije praha X-zraka nadalje obuhvaća vršne vrijednosti na 13,0 1 18,2 stupnjeva 20 (+ 0,2 stupnjeva 20) kada se mjeri uporabom radijacije CuKa. 5.
represents a hydrogen atom, a C1-3 alkyl group or a halogen atom; more preferably a hydrogen atom; and/or 
R3 predstavlja atom vodika, C,.3 alkilnu skupinu ili atom halogena; poželjnije atom vodika; i/ili
taking process air arriving from a compressed air source 30 and subjecting the process air taken in this way to a treatment step which comprises at least one cooling sub-step; 
- <- uzimanja zraka za postupak koji dolazi iz izvora komprimiranog zraka (30) i podvrgavanja na taj način uzetog zraka za postupak koraku obrade koji se sastoji od najmanje jednog pod-koraka hlađenja;
VBP15 or VBP6 for use according to Claim 1, wherein said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 
VBP15 VBP6 VBPI5 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija izabrana iz grupe koja sadrži Duchenne mišićnu distrofiju, mišićnu distrofiju donjih udova, kongentialnu mišićnu distrofiju, facioskapulohumeralnu mišićnu distrofiju, miotoničnu mišićnu distrofiju, okulofaringealnu mišićnu distrofiju, distalnu mišićnu distrofiju i Emery-Dreifuss mišićnu distrofiju.
A stable aqueous aldehyde solution according to claim 4 wherein the alcohol ethoxylate surfactant includes 3 to 9 ethoxylate groups. 
Stabilna vodena otopina aldehida u skladu s patentnim zahtjevom 4 pri čemu alkoholni etoksilat surfaktant uključuje 3 do 9 etoksilatnih grupa.
is O; n is an integer from 1 to 30 
je kisik; te n je cijeli broj od 1 do 30.
an antibody having a heavy chain as shown in SEQ ID NO: 31 and a light chain as shown in SEQ ID NO: 32 and/or 
(v) antitijelom koje ima teški lanac kao što je prikazano u SEK ID BR: 31 i laki lanac kao što je prikazano u SEK ID BR: 32 i/ili
the effluent containing impurities, in the purification unit to produce a purified effluent, and monitoring a pH value of the purified effluent, and if it is less than 6.5, it is adjusted to a value of at least 6.5, after which the purified effluent is discharged into a sea or returned to the exhaust gas scrubber (1,1'), characterized in that the purification unit (2, 2') comprises an effluent circuit (3, 3') including at least one membrane filter (4, 4'), and that the wash water to be purified, i.e. 
ispusta koji sadrži nečistoće, u jedinici za pročišćivanje kako bi se dobilo pročišćeni ispust, i - praćenju vrijednosti pH pročišćenog ispusta, te ako je manja od 6,5, njenom podešavanju do vrijednosti od naznačen time što jedinica za pročišćivanje (2, 2) sadrži ispusni krug (3, 3), koji sadrži najmanje jedan membranski filtar (4, 4'), te što se vodu za ispiranje koju treba pročistiti, tj.
An effective amount of benralizumab for use in the treatment of asthma, wherein benralizumab is administered to an asthma patient, wherein the administration reduces the patient's exacerbation rate, and wherein benralizumab is administered at a dose of 30 mg once every four weeks for twelve weeks and then once every eight weeks. 
HR P20190405 T1 PATENTNI ZAHTJEVI Učinkovita količina benralizumaba za upotrebu u liječenju astme, pri čemu se benralizumab daje pacijentu s astmom, pri čemu primjena smanjuje brzinu pogoršanja, te naznačen time što se benralizumab primjenjuje u dozi od 30 mg jednom svaka četiri tjedna tijekom dvanaest tjedana i zatim jednom svakih osam tjedana.
Single enantiomers of the alkene (II) can be prepared by subjecting RR/SS tetrabenazine to a stereoselective reduction using lithium tri-sec-butyl borohydride to give a mixture of SRR and RSS enantiomers of dihydrotetrabenazine, separating the enantiomers (e.g. by fractional crystallisation) and then dehydrating a separated single enantiomer of dihydrotetrabenazine to give predominantly or exclusively a single enantiomer of the compound of formula (II). 
Pojedinačni enantiomeri alkena (II) se mogu pripremiti podvrgavanjem RR/SS tetrabenazina stereoselektivnoj redukciji uporabom tri-sek-butil borohidrida da bi se dobila smjesa SRR 1 RSS enantiomera dihidrotetrabenazina, odijeljivanjem enatiomera (na primjer frakcijskom kristalizacijom) HR P20080677 T3 i zatim dehidriranjem odijeljenog pojedinog enantiomera dihidrotetrabenazina da bi se dobio predominantno ili potpuno pojedinačni enantiomer spoja formule (Il).
The CD19xCD3 bispecific single chain antibody as used herein is advantageously to be prepared in the form of a pharmaceutical composition for administration to a human pediatric patient diagnosed with acute lymphoblastic leukemia (ALL). 
PATENTNI ZAHTJEVI CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt, naznačeno time što je namijenjeno upotrebi u postupku liječenja, ublažavanja ili otklanjanja pedijatrijske akutne limfoblastične leukemije (ALL) kod pedijatrijskog pacijenta s ALL.
26.The oral composition of item 25, wherein the composition is lyophilized with lyoprotectants comprising 0.2 to 10% maltodextrin and 0.05 to 0.33% yeast extract, 0.05 to 2.5% inulin and 0.1 % yeast extract or 0.3% inulin 
Oralni sastav iz patentnog zahtjeva 5, pri čemu je sastav liofiliziran s lipoprotektantima koji sadrže (a) 0.2 do 10% maltodekstrina i 0.05 do 0.33% ekstrakta kvasca, (b) 0.05 do 2.5% inulina i 0.05 do 0.1% ekstrakta kvasca, ili (c) 0.3% inulina.
In particular, it is within the scope of the present invention to use carrageenan, preferably iota-carrageenan, as an anti-influenza virus effective adjuvant in combination with medicaments useful in the prophylaxis or therapy of infectious and/or inflammatory diseases, allergies and/or conditions of an impaired or suppressed immune system. It was observed that carrageenan may also have immuno-modulating activity, particularly immune system strengthening activity. 
Jota-karagenan namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je jota-karagenan prisutan kao adjuvans djelotvoran protiv paramiksovirusa ili protiv virusa ljudske influence A, uz jednu ili više fiziološki aktivnih tvari koje nisu karagenani, koje se obično upotrebljava u profilaksi ili terapiji infektivnih i/ili upalnih bolesti, alergija i/ili stanja oštećenog ili suprimiranog imunološkog sustava.
LC-MS: M+H+: 444.0 A compound of formula (VIII): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen they are linked to form a phthalimido group. 
(Xla) naznačen time da R' jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R* jest trimetilsilil, a R jest tert-butoksikarbonil; ili R 1 R* uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
passing the hydrolyzed sludge into the hydrolyzed sludge inlet (228) of the heat exchanger (216); 
(€) puštanja hidroliziranog mulja kroz ulaz za hidrolizirani mulj (228) izmjenjivača topline (216);
a ligand which specifically binds to an antigen or receptor on the exterior of the cell, wherein the ligand is conjugated or fused to the mutated PE of any one of claims 1-8, 
(a) citokin, antitijelo 1li fragment antitijela, koji se citokin, antitijelo ili fragment antitijela specifično vežu na neki antigen ili receptor vanjskog dijela spomenute stanice, konjugiran ili fuzioniran sa
This resin was specifically designed to capture immunoglobulins (Boschetti 2000 and Life technologies Inc. 
Ova je smola dizajnirana specifično u svrhu hvatanja imunoglobulina (Boschetti 2000 1 Life technologies Inc.
or R1 and R2 or R2 and R3 can be taken together to form a carbon-carbon double bond; 
ili R1 i R2 ili R2 i R3 oblikuju dvostruku vezu ugljik-ugljik;
Moreover, in the process according to the invention, it is preferred to dry the veneer that is obtained after the cutting/slicing: Preferably, this is carried out at an increased temperature, in particular at a temperature which, dependent on the species of wood, varies between 70 °C and 100 °C. In applying increased temperatures, in particular applying temperatures > 90 °C, usually drying periods up to several minutes are sufficient for a satisfactory drying of the obtained veneer. 
Osim toga, postupak koji je u skladu s ovim izumom je poželjan za sušenje furnira koji je dobiven nakon rezanja/rezanja na kriške. Poželjno je da se to izvodi kod povišene temperature, naročito kod temperature koja, ovisno o vrsti drva, varira između 70%C i 100%C. Kod primjene povišenih temperatura, naročito kod primjene temperatura > 90"C, obično su razdoblja za sušenje do nekoliko minuta dovoljna za zadovoljavajuće sušenje dobivenog furnira.
The process according to any one of claims 1 to 10, wherein the excipients and the active ingredient are sieved before use and/or the granules are sieved or sized before being put into shape. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se ekscipijensi i aktivni sastojci prosijavaju prije upotrebe i / ili se granule prosiju ili odredi veličina prije nego što se oblikuju.
a distal tip portion attached to the second end of the shaft portion; 
distalni vršni dio, spojen na drugi kraj trupa;
The process of claim 1 wherein R' is hydrogen and R is selected from the group consisting of benzyl optionally substituted on the aromatic ring with up to three substituents selected from the group consisting of halogen, cyano, trifluoromethyl; C1-C3 acyl, C7-C11 aroyl, C1-C3 alkylsulfonyl, C6-C10 arylsulfonyl, C1-C4 alkoxycarbonyl, benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from the group consisting of halogen, cyano, trifluoromethyl. The process of claim 2 wherein R is selected from the group consisting of benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl. 
Spoj formule (XI) ili (XIa) [image] naznačen time da R’ jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R’ jest trimetilsilil, a R jest tert-butoksikarbonil; ili R i R’ uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
While it is possible that a compound for use in treatment may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or "active ingredient" as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier. 
Iako je moguće da, za uporabu u liječenju, spoj prema izumu može, kao alternativni način uporabe, biti primijenjen kao sirovina ili čista kemijska supstanca, naravno da je povoljno prikazati spoj ili "aktivni sastojak " kao farmaceutski pripravak ili pripravak koji nadalje sadrži farmaceutski prihvatljivu podlogu.
The method of claim 6, wherein a number of encoded subsets is determined using a last non-zero coefficient position and the selected scan inverse pattern. 
Postupak prema Zahtjevu 6, gdje se broj kodiranih podskupova određuje korištenjem posljednje pozicije koeficijenta različitog od nule odabranog obrasca skeniranja.
The compound or a salt thereof according to claim 1, wherein U is NR15, and VisN. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 1, gdje U je NR15, i V je N.
with a compound of formula HNR1R2. wherein R1 and R2 represent, independently, hydrogen or C1-C5 alkyl, provided that when one of R1 and R2 is hydrogen, the other is not hydrogen; or wherein R1 and R2 together form a C4-C7-alkylene bridge, so that with the inclusion of the nitrogen atom to which they are linked a heterocycle is formed, wherein one -CH2- group of the C4-C7-alkylene bridge, can be replaced by -O-, in the presence of formaldehyde; or 
sa spojem formule HNR1R2 gdje R1 i R2 predstavljaju, nezavisno, vodik ili C1-C5 alkil, uz uvjet da kada je jedan od R1 i R2 vodik, drugi nije vodik; ili gdje R1 i R2 zajedno formiraju C4-C7-alkilenski most, tako da s umetanjem atoma dušika s kojim su spojeni nastane heterocikl, gdje jedna -CH2- skupina u C4-C7-alkilenskom mostu, može biti zamijenjena s -O-, u prisutnosti formaldehida; ili
loading the container of dehydrated organic material into the input end of an equilibration chamber, the equilibration chamber being at the pressure less than atmospheric; 
utovarivanja posude (38) dehidriranog organskog materijala u ulazni kraj (155) ekvilibracijske komore (150), pri čemu je ekvilibracijska komora pri pritisku nižem od atmosferskog;
The methods include: (a) measuring a level of TRL V6 in at least two in vitro samples from the patient, at least one taken in conjunction with administration of the weight-loss pharmaceutical agent to the patient; (b) electronically identifying whether there is a reduction in TRL V6 level associated with the weight loss agent; and (c) assessing a patient's likelihood of favorably responding to the weight loss pharmaceutical agent based on the identifying step. Brief Description of the Figures 
Postupak procjenjivanja vjerojatnosti da pacijent povoljno reagira na farmaceutsko sredstvo za smanjivanje tjelesne težine, naznačen time što se sastoji u: mjerenju koncentracije TRL V6 kod najmanje dva in vitro uzorka iz pacijenta, gdje se najmanje jedan uzima povezano s primjenom farmaceutskog sredstva za smanjivanje tjelesne težine na pacijentu; HR P20110840 T1 elektronskom procjenjivanju je li došlo do smanjivanja razine TRL V6 povezanog s farmaceutskim sredstvom za smjanjivanje tjelesne težine; i procjenjivanju vjerojatnosti da pacijent povoljno reagira na farmaceutsko sredstvo za smjanjivanje tjelesne težine na osnovu koraka elektronskog procjenjivanja.
The aqueous stoving binder of claim 2 wherein the organic acid A23 is a saturated or an unsaturated aliphatic monocarboxylic acid having from 2 to 40 carbon atoms. 
Vodeno vezivno sredstvo za peći prema zahtjevu 1, naznačeno time, da organska kiselina A23 je zasićena ili nezasićena alifatska monokarboksilna kiselina koja ima od 2 do 40 atoma ugljika.
No. 5,712,396, those disclosed by Biller, et al., J. Med. Chem., 31, 1869-1871 (1998) including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Pat. Nos. 4,871,721 and 4,924,024 and in Biller, S. A., Neuenschwander, K., Ponpipom, M. M., and Poulter, C. D., Current Pharmaceutical Design, 2, 1-40 (1996). 
Inhibitori skvalen sintetaze koji su ovdje prikladni za upotrebu uključuju, ali bez ograničenja, a-fosfono-sulfonate koji su prikazani u U.S. Patentnom br. 5,712,396, koje su prikazali Biller, et. al., J.Med.Chem., 31, 18 69-1871 (1998) što uključuje izoprenoid (fosfinil-metil)fosfonate jednako kao i druge poznate inhibitore skvalen sintetaze, npr., kao što je prikazano u U.S. Patentnom br. 4,871,721 i 4,924,024 i u Biller, S.A., Neuenschwander, K., Ponpipom, M.M., i Poulter, CD., Current Pharmaceutical Design, 2, 1-40 (1996).